PMID- 35718995
OWN - NLM
STAT- MEDLINE
DCOM- 20221111
LR  - 20221111
IS  - 1476-5829 (Electronic)
IS  - 1476-5810 (Linking)
VI  - 20
IP  - 4
DP  - 2022 Dec
TI  - The association between symmetric dimethylarginine concentrations and various 
      neoplasms in dogs and cats.
PG  - 846-853
LID - 10.1111/vco.12845 [doi]
AB  - Following the introduction of the symmetric dimethylarginine (SDMA) immunoassay, 
      cases were reported where the SDMA concentration was markedly increased above the 
      reference interval (RI) with neither concurrent increases in serum creatinine 
      (Cr) concentrations nor clinical signs of kidney disease. Many of these animals 
      were also concurrently diagnosed with cancer, most commonly lymphoma. The purpose 
      of the study was to evaluate the association of increased SDMA in dogs and cats 
      with lymphoma and other cancers as compared with age- and breed-matched 
      non-tumour controls. In this retrospective case-control study, serum chemistry 
      results from 1804 tumour cases, and age- and breed-matched non-tumour control 
      animals were used. Matched-pair odds ratios between animals diagnosed with 
      neoplasms and non-tumour controls for dichotomized SDMA values were determined by 
      tumour type. SDMA concentrations were significantly higher in dogs and cats with 
      lymphoma (p < .0001) compared with non-tumour controls. The odds ratio for 
      increased SDMA concentrations in dogs with lymphoma was 10.0 (95% CI, 5.98-16.72) 
      and for cats with lymphoma was 3.04 (95% CI 1.95-4.73). A significant number of 
      canine and feline lymphoma cases had an increased SDMA concentration not 
      associated with an increased Cr concentration (p < .001). Canine and feline 
      lymphoma patients have an increased odds of having a SDMA concentration above the 
      RI at diagnosis. Further characterization and evaluation of dogs and cats with 
      lymphoma is required to help understand the mechanism(s) and the clinical 
      significance of these alterations.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Coyne, Michael J
AU  - Coyne MJ
AUID- ORCID: 0000-0003-4107-2353
AD  - IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine, USA.
FAU - Drake, Corie
AU  - Drake C
AD  - IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine, USA.
FAU - McCrann, Donald J
AU  - McCrann DJ
AD  - IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine, USA.
FAU - Kincaid, David
AU  - Kincaid D
AD  - IDEXX Laboratories, Inc., One IDEXX Drive, Westbrook, Maine, USA.
LA  - eng
PT  - Journal Article
DEP - 20220701
PL  - England
TA  - Vet Comp Oncol
JT  - Veterinary and comparative oncology
JID - 101185242
RN  - 49787G1ULV (symmetric dimethylarginine)
RN  - 0 (Biomarkers)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Cats
MH  - Dogs
MH  - Animals
MH  - *Cat Diseases
MH  - Retrospective Studies
MH  - Case-Control Studies
MH  - Biomarkers
MH  - *Dog Diseases
MH  - Arginine
MH  - *Neoplasms/veterinary
OTO - NOTNLM
OT  - cancer
OT  - canine
OT  - feline
OT  - lymphoma
OT  - matched-pair odds ratio
OT  - protein arginine methyltransferase
EDAT- 2022/06/21 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/06/20 01:33
PHST- 2022/06/15 00:00 [revised]
PHST- 2022/01/13 00:00 [received]
PHST- 2022/06/15 00:00 [accepted]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
PHST- 2022/06/20 01:33 [entrez]
AID - 10.1111/vco.12845 [doi]
PST - ppublish
SO  - Vet Comp Oncol. 2022 Dec;20(4):846-853. doi: 10.1111/vco.12845. Epub 2022 Jul 1.